{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"ADIL","limit":50},"count":50,"signals":[{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":72,"context":"nditions may have a negative impact on our business. | | | | | Health care policy changes, including legislation reforming the U.S. health care system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations and cash flows. | | | | A government shutdown or inadequate funding of the FDA could adversely affect our business | | *Risks Related to Our Securi","filed_date":"2026-03-05","accession":"0001213900-26-024175","full_text":"https://origin.rootz.global/static/filing/0001213900-26-024175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"he principal provisions of the 2017 equity incentive plan are summarized below. *Administration* The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee has full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan, to sel","filed_date":"2026-03-05","accession":"0001213900-26-024175","full_text":"https://origin.rootz.global/static/filing/0001213900-26-024175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"t items of business will be voted on at the 2025 Annual Meeting? A:The five (5)items of business scheduled to be voted on at the 2025 Annual Meeting are: (1)the election of the two (2)ClassI nominees named herein as directors; (2)the ratification of the appointment of CBIZ as our independent registered public accounting firm for our fiscal year ending on December31, 2025; (3)approval of the issuance of up to an aggregate","filed_date":"2025-06-10","accession":"0001213900-25-053170","full_text":"https://origin.rootz.global/static/filing/0001213900-25-053170.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":70,"context":"nditions may have a negative impact on our business. | | | | | Health care policy changes, including legislation reforming the U.S. health care system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations and cash flows. | | *Risks Related to Our Securities and Investing in Our Securities* ** | | | Certain of our shareholders have sufficient voting","filed_date":"2025-03-04","accession":"0001213900-25-019771","full_text":"https://origin.rootz.global/static/filing/0001213900-25-019771.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":23,"context":"5, 50% of his current base salary as a consultant to us, and (iii) from and after March 31, 2025, $350 an hour as a consultant to us on an as needed basis. On November 1, 2024, our board of directors appointed Vinay Shah as our Chief Financial Officer, effective November 16, 2024. In connection with his appointment, we entered into an employment agreement with Mr. Shah (the Shah Employment Agreement) to employ Mr. Shah as our Chi","filed_date":"2025-03-04","accession":"0001213900-25-019771","full_text":"https://origin.rootz.global/static/filing/0001213900-25-019771.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":35,"context":"r of shares of common stock that we will have authority to grant under the plan from 500,000 to 2,000,000; (4)    to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in this proxy statement; (5)    to approve, on an advisory basis, a frequency for holding an advisory vote on executive compensation; and (6)  ","filed_date":"2024-09-27","accession":"0001213900-24-082805","full_text":"https://origin.rootz.global/static/filing/0001213900-24-082805.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":23,"context":"such term in Section 3(v). Issuer Free Writing Prospectus shall mean an issuer free writing prospectus, as defined in Rule 433. 2 Losses shall have the meaning ascribed to such term in Section 7(d). Material Adverse Effect shall have the meaning ascribed to such term in Section 3(b). Material Permits shall have the meaning ascribed to such term in Section 3(t). Net Proceeds shall have the meaning ascribed to such term","filed_date":"2024-04-18","accession":"0001213900-24-034186","full_text":"https://origin.rootz.global/static/filing/0001213900-24-034186.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":67,"context":"conditions may have a negative impact on our business. | | | | Health care policy changes, including legislation reforming the U.S. health care system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations and cash flows. | | iv *Risks Related to Our Securities and Investing in Our Securities* ** | | Certain of our shareholders have sufficient voting","filed_date":"2024-04-01","accession":"0001213900-24-028701","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028701.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":18,"context":"principal provisions of the 2017 equity incentive plan are summarized below. **Administration** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2024-04-01","accession":"0001213900-24-028701","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028701.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":16,"context":";    The three (3) items of business scheduled to be voted on at the 2023 Annual Meeting are: (1) the election of the two (2) Class II nominees named herein as directors; (2) the ratification of the appointment of Marcum as our independent registered public accounting firm for our fiscal year ending on December 31, 2023; and (3) the approval of","filed_date":"2023-10-02","accession":"0001013762-23-000102","full_text":"https://origin.rootz.global/static/filing/0001013762-23-000102.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"product candidate will require extensive clinical and other testing. | | | | | Our clinical trials may fail to demonstrate adequately the safety and efficacy of AD04. | | | | | Delays in the enrollment of patients in our clinical trials could impact our regulatory approvals. | | | | | Our success will be dependent upon adoption of our products by physicians. | | | | | Rapid technological cha","filed_date":"2023-03-30","accession":"0001213900-23-024719","full_text":"https://origin.rootz.global/static/filing/0001213900-23-024719.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":22,"context":"onditions may have a negative impact on our business. | | | | | Health care policy changes, including legislation reforming the U.S. health care system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations and cash flows. | | *Risks Related to Our Securities and Investing in Our Securities* ** | | | Certain of our shareholders have sufficient voting p","filed_date":"2023-03-30","accession":"0001213900-23-024719","full_text":"https://origin.rootz.global/static/filing/0001213900-23-024719.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"principal provisions of the 2017 equity incentive plan are summarized below. **Administration** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2023-03-30","accession":"0001213900-23-024719","full_text":"https://origin.rootz.global/static/filing/0001213900-23-024719.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"0;    The three (3) items of business scheduled to be voted on at the 2022 Annual Meeting are: (1) the election of the two (2) Class I nominees named herein as directors; (2) the ratification of the appointment of Friedman as our independent registered public accounting firm for our fiscal year ending on December 31, 2022; (3) the approval of an","filed_date":"2022-09-01","accession":"0001213900-22-053250","full_text":"https://origin.rootz.global/static/filing/0001213900-22-053250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":20,"context":"onitoring and close-out activities are underway (a total of 303 patients were recruited and then randomized in the trial, however, one subject never initiated treatment and has been excluded from enrollment numbers and will not be included in the full analysis data set or efficacy analysis for the trial). ONWARD trial data is expected to be unblinded and analyzed in the second quarter of 2022. We bel","filed_date":"2022-03-28","accession":"0001213900-22-015562","full_text":"https://origin.rootz.global/static/filing/0001213900-22-015562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":20,"context":"onditions may have a negative impact on our business. | | | | | Health care policy changes, including legislation reforming the U.S. health care system and other legislative initiatives, may have a material adverse effect on our financial condition, results of operations and cash flows. | | *Risks Related to Our Securities and Investing in Our Securities* ** | | | Certain of our shareholders have sufficient voting","filed_date":"2022-03-28","accession":"0001213900-22-015562","full_text":"https://origin.rootz.global/static/filing/0001213900-22-015562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"principal provisions of the 2017 equity incentive plan are summarized below. **Administration** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2022-03-28","accession":"0001213900-22-015562","full_text":"https://origin.rootz.global/static/filing/0001213900-22-015562.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":18,"context":"ee quarters of 2020, the Company experienced delays in certain countries in obtaining regulatory approval required to commence the trial in such countries, resulting in significantly slowed trial enrollment (see Other Uncertainties below). Enrollment rates subsequently improved, and the the Phase 3 trial is now fully enrolled. The Company presently projects completion of the Phase 3 clinical trial in","filed_date":"2021-11-15","accession":"0001213900-21-058840","full_text":"https://origin.rootz.global/static/filing/0001213900-21-058840.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":11,"context":"1 Annual Meeting? A:     The three (3) items of business scheduled to be voted on at the 2021 Annual Meeting are: (1) the election of the two (2) Class III nominees named herein as directors; (2) the ratification of the appointment of Friedman as our independent registered public accounting firm for our fiscal year ending on December 31, 2021; and (3) the approval of an amendment to our","filed_date":"2021-08-23","accession":"0001213900-21-044137","full_text":"https://origin.rootz.global/static/filing/0001213900-21-044137.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ee quarters of 2020, the Company experienced delays in certain countries in obtaining regulatory approval required to commence the trial in such countries, resulting in significantly slowed trial enrollment (see Other Uncertainties below). Enrollment has since improved, though enrollment in higher cost sites in Scandinavia have recovered more quickly than in lower cost sites in Central and Eastern Eu","filed_date":"2021-08-12","accession":"0001213900-21-042118","full_text":"https://origin.rootz.global/static/filing/0001213900-21-042118.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"ee quarters of 2020, the Company experienced delays in certain countries in obtaining regulatory approval required to commence the trial in such countries, resulting in significantly slowed trial enrollment (see Other Uncertainties below). Enrollment has since improved, though enrollment in higher cost sites in Scandinavia have recovered more quickly than in lower cost sites in Central and Eastern Eu","filed_date":"2021-05-17","accession":"0001213900-21-027140","full_text":"https://origin.rootz.global/static/filing/0001213900-21-027140.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"ical trial of AD04 for the treatment of AUD | | | All 25 planned investigative sites are active. | | | | | 35% of the planned 290 subjects in the ONWARD trial were enrolled | | | | | The enrollment rate has increased for four consecutive months and the early termination rate has been lower than expected. | | | | | AD04 has been well tolerated with no serious adverse events having been rep","filed_date":"2021-03-22","accession":"0001213900-21-017009","full_text":"https://origin.rootz.global/static/filing/0001213900-21-017009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"uct candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences such as incurring product liability lawsuits | | iii | | | We will continue to be subject to ongoing and extensive regulatory requirements even after regulatory approval, and compliance with such r","filed_date":"2021-03-22","accession":"0001213900-21-017009","full_text":"https://origin.rootz.global/static/filing/0001213900-21-017009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":49,"context":"Documents, Financial Statements; Disclosure Controls and Procedures; Internal Controls Over Financial Reporting; Accountants | 11 | | | Section 5.7. | Subsidiaries | 13 | | | Section 5.8. | No Material Adverse Effect or Material Adverse Change | 14 | | | Section 5.9. | No Undisclosed Liabilities | 14 | | | Section 5.10. | No Undisclosed Events or Circumstances | 14 | | | Section 5.11. | Indebtedness; Sol","filed_date":"2020-11-24","accession":"0001213900-20-039059","full_text":"https://origin.rootz.global/static/filing/0001213900-20-039059.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":23,"context":"ee quarters of 2020, the Company experienced delays in certain countries in obtaining regulatory approval required to commence the trial in such countries, resulting in significantly slowed trial enrollment (see *Other Uncertainties* below). Enrollment has since improved, though enrollment in higher cost sites in Scandinavia have recovered more quickly than in lower cost sites in Central and Eastern","filed_date":"2020-11-13","accession":"0001213900-20-036925","full_text":"https://origin.rootz.global/static/filing/0001213900-20-036925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":19,"context":"20 Annual Meeting? A:     The three (3) items of business scheduled to be voted on at the 2020 Annual Meeting are: (1) the election of the two (2) Class II nominees named herein as directors; (2) the ratification of the appointment of Friedman as our independent registered public accounting firm for our fiscal year ending on December 31, 2020; and (3) the approval of an amendment to our","filed_date":"2020-07-21","accession":"0001213900-20-018019","full_text":"https://origin.rootz.global/static/filing/0001213900-20-018019.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ncertain, but may continue the downward pressure on medical device pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs, which could have a material adverse effect on our business operations. Efforts to significantly amend or repeal the ACA continue and if passed could have a significant impact on important aspects of our business including medical device and d","filed_date":"2020-03-20","accession":"0001213900-20-007020","full_text":"https://origin.rootz.global/static/filing/0001213900-20-007020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":20,"context":"at the 2019 Annual Meeting? A:     The three (3) items of business scheduled to be voted on at the 2019 Annual Meeting are: (1) the election of the two (2) nominees named herein as directors; (2) the ratification of the appointment of Friedman as our independent registered public accounting firm for our fiscal year ending on December 31, 2019; and (3) the approval of an amendment to our","filed_date":"2019-07-08","accession":"0001213900-19-012205","full_text":"https://origin.rootz.global/static/filing/0001213900-19-012205.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":17,"context":"ncertain, but may continue the downward pressure on medical device pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs, which could have a material adverse effect on our business operations. Efforts to significantly amend or repeal the ACA continue and if passed could have a significant impact on important aspects of our business including medical device and d","filed_date":"2019-02-19","accession":"0001213900-19-002769","full_text":"https://origin.rootz.global/static/filing/0001213900-19-002769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"vailable or, if available, successful. Without additional funding, management would be required to delay, scale back or eliminate some or all of its research and development which would likely have a material adverse effect on the Company. Generally, the Companys operations are also subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to:","filed_date":"2018-11-14","accession":"0001213900-18-015559","full_text":"https://origin.rootz.global/static/filing/0001213900-18-015559.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":14,"context":"vailable or, if available, successful. Without additional funding, management would be required to delay, scale back or eliminate some or all of its research and development which would likely have a material adverse effect on the Company. Generally, the Companys operations are also subject to a number of factors that can affect its operating results and financial condition. Such factors include, but are not limited to:","filed_date":"2018-09-10","accession":"0001213900-18-012298","full_text":"https://origin.rootz.global/static/filing/0001213900-18-012298.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":97,"match_count":9,"context":"ovisions of the 2017 equity incentive plan are summarized below. | | 72 | | | **Administration** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2021-03-22","accession":"0001213900-21-017009","full_text":"https://origin.rootz.global/static/filing/0001213900-21-017009.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":92,"match_count":9,"context":"ipal provisions of the 2017 equity incentive plan are summarized below. **Administration** ** ** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2019-02-19","accession":"0001213900-19-002769","full_text":"https://origin.rootz.global/static/filing/0001213900-19-002769.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":87,"match_count":9,"context":"shall have the meaning specified in the preamble to this Agreement. Lien means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other restriction. Material Adverse Effect shall mean any effect on the business, operations, properties, or financial condition of the Company that is material and adverse to the Company and/or any condition, circumstance, or situation that","filed_date":"2024-12-18","accession":"0001213900-24-110191","full_text":"https://origin.rootz.global/static/filing/0001213900-24-110191.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":87,"match_count":9,"context":"shall have the meaning specified in the preamble to this Agreement. Lien means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right, or other restriction. Material Adverse Effect shall mean any effect on the business, operations, properties, or financial condition of the Company that is material and adverse to the Company and/or any condition, circumstance, or situation that","filed_date":"2023-06-02","accession":"0001213900-23-045360","full_text":"https://origin.rootz.global/static/filing/0001213900-23-045360.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":86,"match_count":7,"context":"se, the Company would be required to delay, scale back or eliminate some or all of its research and development programs or delay its approach to regulators concerning AD04, which would likely have a material adverse effect on the Company and its financial statements. 5 The Companys continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt f","filed_date":"2022-11-14","accession":"0001213900-22-071643","full_text":"https://origin.rootz.global/static/filing/0001213900-22-071643.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":86,"match_count":7,"context":"se, the Company would be required to delay, scale back or eliminate some or all of its research and development programs or delay its approach to regulators concerning AD04, which would likely have a material adverse effect on the Company and its financial statements. 5 The Companys continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt f","filed_date":"2022-08-15","accession":"0001213900-22-047638","full_text":"https://origin.rootz.global/static/filing/0001213900-22-047638.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":82,"match_count":9,"context":"principal provisions of the 2017 equity incentive plan are summarized below. **Administration** The 2017 equity incentive plan generally is administered by our Compensation Committee, which has been appointed by the board of directors to administer the 2017 equity incentive plan. The Compensation Committee will have full authority to establish rules and regulations for the proper administration of the 2017 equity incentive plan,","filed_date":"2020-03-20","accession":"0001213900-20-007020","full_text":"https://origin.rootz.global/static/filing/0001213900-20-007020.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":75,"match_count":5,"context":"cceptable terms, or at all. Without additional funding, the Company would be required to delay, scale back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company and its financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabil","filed_date":"2020-11-13","accession":"0001213900-20-036925","full_text":"https://origin.rootz.global/static/filing/0001213900-20-036925.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":75,"match_count":5,"context":"cceptable terms, or at all. Without additional funding, the Company would be required to delay, scale back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company and its financial statements. 5 Other Uncertainties Generally, this industry subjects the Company to a number of other risks and uncertainties that can affect its operating results an","filed_date":"2020-08-13","accession":"0001213900-20-021918","full_text":"https://origin.rootz.global/static/filing/0001213900-20-021918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":74,"match_count":8,"context":"al information regarding the Merger. ** Inducement Grants The Company granted inducement non-statutory stock options to purchase an aggregate of 557,249 shares of common stock to, the Companys newly appointed chief development officer and executive vice president of strategy respectively, on June 12, 2026, at an exercise price of $2.98 per share, as a material inducement to entering employment with the Company. These options will","filed_date":"2026-08-14","accession":"0001213900-26-090051","full_text":"https://origin.rootz.global/static/filing/0001213900-26-090051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"roduct candidate will require extensive clinical and other testing. | | | | | Our clinical trials may fail to demonstrate adequately the safety and efficacy of AD04. | | | | | Delays in the enrollment of patients in our clinical trials could impact our regulatory approvals. | | | | | Our success will be dependent upon adoption of our products by physicians. | | | | | Rapid technological c","filed_date":"2026-03-05","accession":"0001213900-26-024175","full_text":"https://origin.rootz.global/static/filing/0001213900-26-024175.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"nd quarters of 2020, the Company experienced delays in certain countries in obtaining regulatory approval required to commence the trial in such countries, resulting in significantly slowed trial enrollment (see *Other Uncertainties* below). Enrollment has since improved and, with the additional capital from the June offering, the Company presently projects that it will be able to reach database lock","filed_date":"2020-08-13","accession":"0001213900-20-021918","full_text":"https://origin.rootz.global/static/filing/0001213900-20-021918.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":71,"match_count":7,"context":"al disruption to the Companys operations. In such case, the Company would be required to delay, scale back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company and its financial statements. The Companys continued operations will depend on its ability to raise additional capital through various potential sources, such as equity and/or debt fin","filed_date":"2022-05-16","accession":"0001213900-22-026590","full_text":"https://origin.rootz.global/static/filing/0001213900-22-026590.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":70,"match_count":5,"context":"gation The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Companys liquidity, financial condition, and cash flows. As of June 30, 2026, the Company did not have any pending legal actions. 11 SEGMENT REPORTING The Company has one reportable operating","filed_date":"2026-08-14","accession":"0001213900-26-090051","full_text":"https://origin.rootz.global/static/filing/0001213900-26-090051.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":68,"match_count":6,"context":"gation The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Companys liquidity, financial condition, and cash flows. As of September 30, 2025, the Company did not have any pending legal actions. **** **8 SEGMENT REPORTING** The Company has one reportab","filed_date":"2025-11-13","accession":"0001213900-25-109979","full_text":"https://origin.rootz.global/static/filing/0001213900-25-109979.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":65,"match_count":5,"context":"egic plans or transactions. Without additional funding, the Company would be required to delay, scale back or eliminate some or all of its research and development programs, which would likely have a material adverse effect on the Company and its financial statements. The financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and cla","filed_date":"2020-05-14","accession":"0001213900-20-012328","full_text":"https://origin.rootz.global/static/filing/0001213900-20-012328.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":64,"match_count":8,"context":",063 --- EX-99.1 2 ea146718ex99-1_adialpharma.htm PRESS RELEASE ISSUED BY ADIAL PHARMACEUTICALS, INC., DATED AUGUST 31, 2021 **Exhibit 99.1** ** ** ** ** ** ** **ADIAL PHARMACEUTICALS EXCEEDS ENROLLMENT TARGET IN ONWARD PHASE 3 TRIAL OF AD04 FOR THE TREATMENT OF PATIENTS WITH ALCOHOL USE DISORDER** ** ** *ONWARD trial enrollment closed; trial completion expected in Q1 2022* ** ** **Charlottesvill","filed_date":"2021-08-31","accession":"0001213900-21-045799","full_text":"https://origin.rootz.global/static/filing/0001213900-21-045799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"roduct candidate will require extensive clinical and other testing. | | | | | Our clinical trials may fail to demonstrate adequately the safety and efficacy of AD04. | | | | | Delays in the enrollment of patients in our clinical trials could impact our regulatory approvals. | | | | | Our success will be dependent upon adoption of our products by physicians. | | | | | Rapid technological c","filed_date":"2025-03-04","accession":"0001213900-25-019771","full_text":"https://origin.rootz.global/static/filing/0001213900-25-019771.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"ADIL","company":"ADIAL PHARMACEUTICALS, INC.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"Our product candidate will require extensive clinical and other testing. | | | | Our clinical trials may fail to demonstrate adequately the safety and efficacy of AD04. | | | | Delays in the enrollment of patients in our clinical trials could impact our regulatory approvals. | | | | Our success will be dependent upon adoption of our products by physicians. | | | | Rapid technological change","filed_date":"2024-04-01","accession":"0001213900-24-028701","full_text":"https://origin.rootz.global/static/filing/0001213900-24-028701.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"9e4e9dbb1f2f9b636c684b31192c895d3289222ff9a8c02959cba89cc5729b65","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"24a2975f2ed22c03f2d875b1a0b9c1ebb4a53f02cc45e43c10aba297b4474957","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256() || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":12,"hourly_limit":500,"remaining":488,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}